Immunothérapie des lymphomes. (French)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Alternate Title:
      Immunotherapy of lymphomas. (English)
    • Abstract:
      Rituximab is the first monoclonal antibody to have been registered for the treatment of aggressive and indolent, untreated or relapsed B-cell lymphomas. The combination of rituximab with chemotherapy, such as R-CHOP, has the highest efficacy ever described with any chemotherapy regimen. Radio-labeled antibodies have a potential role that remains to be defined. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Le Rituximab est le premier anticorps monoclonal autorisé dans le traitement des lymphomas agressifs ou indolents, en première ligne ou en rechute. Sa combinaison à la chimiothérapie, comme dans le régime R-CHOP, a démontré une efficacité supérieure à celle de la chimiothérapie seule. Les anticorps radio-marqués ont un rôle potentiel qui reste à préciser. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Oncologie (Tech Science Press) is the property of Tech Science Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)